A retrospective real-world study of 101 patients treated primarily in community oncology settings reported an 80.2% overall response rate to teclistamab for relapsed or refractory multiple myeloma. The data describe outcomes outside of highly controlled trial environments and across practical treatment pathways. The findings add to growing evidence that BCMA-directed bispecific antibodies can translate into consistent response rates in broader care settings, where dosing logistics, monitoring, and supportive care vary. For operators and payers, the dataset offers a benchmark for expected performance and can inform patient selection and capacity planning as bispecific adoption continues.